Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Ups with Vision

This article was originally published in Start Up

Executive Summary

The high visibility of new laser technologies for vision correction or refractive surgery, a widely-publicized consumer market, has obscured the fact that there are even greater needs in the ophthalmic market; 13 million patients suffer from age-related macular degeneration, 4-6 million patients suffer from diabetic retinopathy, and 89 million Americans are troubled by "old vision" or presbyopia.

You may also be interested in...



NeuroVision Inc.

NeuroVision Inc. is looking behind the eye to correct vision problems. It is targeting the back of the brain with a Web-based, noninvasive, patient-specific treatment designed to re-wire the neural connections responsible for vision. The company will first target adult amblyopia, and then move on to presbyopia, myopia and other visual disorders.

Visual Pathways Inc.

Many of the leading causes of blindness are controllable, even curable, provided that they are detected at an early stage. But the time-consuming and uncomfortable nature of current screening techniques can be a deterrent. Visual Pathways Inc. is developing a series of precise, automatic vision care diagnostics aimed at streamlining the screening process to make it more comfortable for patients.

Quest Vision Inc.

Quest Vision has developed an intraocular lens that accommodates the way the natural lens does, that is, it changes shape for near or distance vision. Originally designed for cataract patients, the lens will also serve 89 million older Americans suffering from presbyopia.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel